Chemoradiation Versus Esophagectomy for Locally Advanced Esophageal Cancer

Condition(s) studied

Investigational drug(s) / intervention(s)

CRT: Drug: Capecitabine(Aibin) capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total Other Names: Aibin Drug: Oxaliplatin(Aiheng) Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V. Other Names: Aiheng cisplatin: 75mg/m2 d1，29 or d1, 29, 57, 85. 5-Fu：750mg/m2 CIV24h d1-4，d29-32 or d1-4，d29-32, d57-60, d85-88. Radiation: Radiotherapy concurrent radiotherapy：IMRT radiotherapy 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity

surgery: The patients randomized to receive either standard esophagectomy will have the operation performed in an open manner with two-field lymphadenectomy

Study summary

The aim of this study is to compare outcomes in Chinese patients with locally advanced resectable esophageal squamous cell cancer who have received either surgery or definitive chemoradiation (CRT) by the randomized, open-label, multicenter trial.

Eligibility

Primary outcome measure(s)

• 2-year disease-free survival rate — 2 year
  The percent of 2 year disease-free survival after random allocation, percent

Trial sites (2)

More The First Affiliated Hospital of Henan University of Science and Technology trials in China

Other trials for the same condition